Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hematologic Diseases: early-phase trial registry
6 of 18 indexed Hematologic Diseases trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #953 of 28,707 conditions by registered trial count.
18 US clinical trials · 6 currently recruiting · #953 of 28,707 conditions by registered trial count
Hematologic Diseases: 18 US clinical trials tracked, 6 recruiting.
Hematologic Diseases is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Vertex Pharmaceuticals Incorporated, running 2 of these trials.
Enrollment posture brief
Registry condition hematologic-diseases
OPEN 6 | RECR 33% | LATE 3 | EARLY 5 | RANK #953 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Hematologic Diseases lists 6 open slots (33% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hematologic Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hematologic Diseases is recruiting below its size-band peers.
6 of 18 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hematologic Diseases trials is spread across many organizations.
Vertex Pharmaceuticals Incorporated accounts for 2 of 18 trials (11.1%). 16 distinct sponsors appear on at least one study for this condition label.
-
Typical Hematologic Diseases enrolment sits around 81 participants.
Median target enrolment is 81 among the 18 trials that report a genuine target (sentinel values excluded). 10 of those (55.6%) plan for fewer than 100 participants.
-
Hematologic Diseases research is mostly interventional.
13 interventional and 5 observational studies make up this index (72.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
18 total, page 1 of 1
The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research
Invivoscribe
NCT06222164
HEME Home Transfusion Program
Dana-Farber Cancer Institute
NCT06487247
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
Alice Bertaina
NCT04249830
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
OriCell Therapeutics Co.
NCT06271252
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Vertex Pharmaceuticals Incorporated
NCT05477563
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback
Porteus, Matthew, MD
NCT04640987
Gulf Long-Term Follow-Up Study
National Institute of Environmental Health Sciences (NIEHS)
NCT01287000
Multimodal Sexual Dysfunction Intervention In HCT
Massachusetts General Hospital
NCT03803696
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
University of Michigan Rogel Cancer Center
NCT03842696
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
Vertex Pharmaceuticals Incorporated
NCT05356195
Evaluation, Treatment, and Training for Patients With Blood Disorders
National Heart, Lung, and Blood Institute (NHLBI)
NCT00001397
Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease
Duke University
NCT04584528
A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome
National Institutes of Health Clinical Center (CC)
NCT00001839
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
National Cancer Institute (NCI)
NCT00001338
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
National Heart, Lung, and Blood Institute (NHLBI)
NCT00029380
HLA Matching - Unrelated Umbilical Cord Blood Transplantation
Ann & Robert H Lurie Children's Hospital of Chicago
NCT00179946
Patient-Reported Outcomes Version of Common Terminology Criteria (CTCPRO) Cognitive Debriefing
M.D. Anderson Cancer Center
NCT00909207
Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
Emory University
NCT00231309
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Hematologic Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hematologic Diseases trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hematologic Diseases page
18 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Hematologic Diseases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Vertex Pharmaceuticals Incorporated sponsors the most Hematologic Diseases trials on record, review their full trial history before evaluating a specific study. See Vertex Pharmaceuticals Incorporated's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hematologic Diseases condition card totals 18 registered trials; most-linked intervention CTX001; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.